SILVERARC CAPITAL MANAGEMENT LLC
Q3 2025 Form 13-F
BOSTON, MASSACHUSETTS
CIK 0001816307
· CRD 304220
· SEC-registered investment adviser
Consolidated report · includes
1 manager
since Q4 2020
$741.6M Reported Value Total
SILVERARC CAPITAL MANAGEMENT, LLC reports 7 total accounts under management (AUM). There are 7 discretionary accounts valued at $1,037,411,213, and 0 non-discretionary accounts.
Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Private funds (Form ADV)
3 funds
· $935.3M gross asset value
Hedge Fund: $913.6M · Venture Capital Fund: $21.7M
Source: Form ADV filed 2026-03-30
Reported value
$741.6M
Quarter over quarter
+29.8%
Holdings
73
Top-10 concentration
43.5%
Filing Structure
Reports holdings for
- SILVERARC CAPITAL LLC · File #028-20993 · since Q4 2020
Key People
Form ADV owners & control persons
Devesh Sharad Gandhi
FOUNDER & CHIEF EXECUTIVE OFFICER
Paul Nmn Brauer
CHIEF COMPLIANCE OFFICER
Amanda Lynn Goodell
CHIEF FINANCIAL OFFICER
Filing Navigation
13F Metrics
Loading 13F Metrics
Q3 2025 13F record
Q3 2025 13F filing summary
| Period of report | September 30, 2025 |
|---|---|
| Filed | November 12, 2025 |
| Form | 13F-HR |
| Reported value | $741.6M |
| Positions | 73 |
| Change in reported value | +36.8% |
| New positions | 30 |
| Exited positions | 14 |
| Position turnover | 50.6% |
| Top-10 concentration | 43.5% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 13, 2026
|
65 | $962.2M |
|
Q1 2026 13F
Filed May 14, 2026
|
67 | $979.8M |
|
Q4 2025 13F
Filed Feb 12, 2026
|
64 | $720.1M |
|
Q3 2025 13F
Filed Nov 12, 2025
|
73 | $741.6M |
|
Q2 2025 13F
Filed Aug 14, 2025
|
57 | $542.3M |
|
Q1 2025 13F
Filed May 14, 2025
|
67 | $489.0M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
58 | $457.2M |
|
Q3 2024 13F
Filed Nov 14, 2024
|
68 | $445.3M |
|
Q2 2024 13F
Filed Aug 14, 2024
|
66 | $423.9M |
|
Q1 2024 13F
Filed May 15, 2024
|
73 | $360.1M |
|
Q4 2023 13F
Filed Feb 14, 2024
|
64 | $336.0M |
|
Q3 2023 13F
Filed Nov 13, 2023
|
68 | $329.8M |
|
Q2 2023 13F
Filed Aug 14, 2023
|
77 | $323.3M |
|
Q1 2023 13F
Filed May 15, 2023
|
67 | $242.3M |
|
Q4 2022 13F
Filed Feb 14, 2023
|
81 | $349.6M |
|
Q3 2022 13F
Filed Oct 28, 2022
|
68 | $295.6M |
|
Q2 2022 13F
Filed Jul 25, 2022
|
59 | $324.8M |
|
Q1 2022 13F
Filed May 13, 2022
|
65 | $241.6M |
|
Q4 2021 13F
Filed Feb 14, 2022
|
68 | $246.8M |
|
Q3 2021 13F
Filed Nov 15, 2021
|
79 | $176.9M |
3 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q3 2025
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | ABVX ABIVAX SA | $45.8M | 6.18% |
| 2 | RYTM RHYTHM PHARMACEUTICALS INC | $37.4M | 5.04% |
| 3 | RNA AVIDITY BIOSCIENCES INC | $36.8M | 4.96% |
| 4 | NUVL NUVALENT INC | $32.2M | 4.34% |
| 5 | URGN UROGEN PHARMA LTD | $31.5M | 4.24% |
| 6 | AKRO AKERO THERAPEUTICS INC | $30.6M | 4.12% |
| 7 | INSM INSMED INC | $29.8M | 4.01% |
| 8 | DNTH DIANTHUS THERAPEUTICS INC | $26.6M | 3.58% |
| 9 | QURE UNIQURE NV | $26.6M | 3.58% |
| 10 | CGON CG ONCOLOGY INC | $25.7M | 3.47% |
| 11 | UTHR P UNITED THERAPEUTICS CORP DEL | $25.1M | 3.39% |
| 12 | ORIC ORIC PHARMACEUTICALS INC | $23.4M | 3.15% |
| 13 | CDTX CIDARA THERAPEUTICS INC | $21.2M | 2.85% |
| 14 | GUTS FRACTYL HEALTH INC | $16.9M | 2.27% |
| 15 | KALV KALVISTA PHARMACEUTICALS INC | $16.6M | 2.24% |
| 16 | KOD KODIAK SCIENCES INC | $16.4M | 2.21% |
| 17 | RARE C ULTRAGENYX PHARMACEUTICAL IN | $15.9M | 2.14% |
| 18 | GOSS GOSSAMER BIO INC | $12.6M | 1.69% |
| 19 | COGT COGENT BIOSCIENCES INC | $11.7M | 1.58% |
| 20 | CYTK CYTOKINETICS INC | $11.6M | 1.56% |
Values as reported on the Q3 2025 Form 13F. Every position is in the holdings table below.